127 completed, 37 recruiting, 36 terminated, 34 active not recruiting. 134 Phase 2, 97 Phase 1, 22 Phase 3, 19 Not applicable, 3 Early Phase 1.
Follow Uveal Neoplasms: new trials by email Literature Review of Uveal Neoplasms trials Research Report on Uveal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Not yet recruiting | University of California, San Diego | 34 | 2026-11-01 | 2026-09-03 |
| Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma RBP-01 - Uveal Melanoma | Phase 1 / Phase 2 | Not yet recruiting | ReBio Pharma | 30 | 2026-10-01 | 2026-08-05 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
| Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma Nivolumab & Ipilimumab - Uveal Melanoma | Phase 1 | Recruiting | Inge Marie Svane | 15 | 2026-06-29 | 2026-07-01 |
| A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma Observational - Choroidal Melanoma, Indeterminate Lesions | Enrolling by invitation | Aura Biosciences | 100 | 2026-03-27 | 2026-08-19 | |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide - Unresectable Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-04 |
| Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis roginolisib - Uveal Melanoma, Metastatic | Phase 1 | Recruiting | St Vincent's Hospital, Sydney | 8 | 2026-02-01 | 2026-04-23 |
| Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver Melphalan through Percutaneous Hepatic Perfusion - Uveal Melanoma | Not applicable | Recruiting | Massachusetts General Hospital | 10 | 2026-01-27 | 2026-03-11 |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma Darovasertib, Primary Local Therapy - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 520 | 2026-01-25 | 2026-05-06 |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2025-12-31 | 2026-03-31 |
| Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma Cyclophosphamide, Fludarabine, Interleukin-2 - Melanoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2025-12-03 | 2026-06-26 |
| Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. - Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic | Phase 1 / Phase 2 | Recruiting | Novelwise Pharmaceutical Corporation | 36 | 2025-11-20 | 2025-11-28 |
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects Non-interventional, digital, patient-reported, study - Choroidal Melanoma, Indeterminate Lesions | Active not recruiting | Aura Biosciences | 15 | 2025-11-12 | 2026-10-22 | |
| Tebentafusp-tebn With LDT in Metastatic UM Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | Thomas Jefferson University | 109 | 2025-10-15 | 2026-07-21 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
Showing 20 of 281. Sign in to see all of them.
Uveal Melanoma (279) · Melanoma (125) · Neoplasm Metastasis (33) · Neoplasms (17) · Carcinoma, Renal Cell (14) · Eye Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (13) · Breast Neoplasms (11) · Carcinoma, Hepatocellular (11) · Sarcoma (10) · Lung Neoplasms (9) · Small Cell Lung Carcinoma (9) · Squamous Cell Carcinoma of Head and Neck (9) · Osteosarcoma (8) · Colorectal Neoplasms (7)
Eye Diseases (281) · Neoplasms by Histologic Type (281) · Neoplasms by Site (281) · Neoplasms, Nerve Tissue (281) · Neuroectodermal Tumors (281) · Nevi and Melanomas (281) · Neoplasms, Germ Cell and Embryonal (280) · Uveal Diseases (280) · Neuroendocrine Tumors (279) · Eye Neoplasms (267) · Neoplasms (264) · Melanoma (156) · Skin Diseases (130) · Skin and Connective Tissue Diseases (130)
Ipilimumab (29) · Nivolumab (23) · pembrolizumab (14) · Cyclophosphamide (10) · incomplete Freund's adjuvant (10) · Interleukin-2 (9) · Melphalan (9) · CTLA-4 Antigen (8) · Dacarbazine (7) · MART-1 Antigen (7) · Temozolomide (7) · sargramostim (7) · tebentafusp (7) · Ranibizumab (6) · Bevacizumab (5)
National Cancer Institute (NCI) (22) · Institut Curie (13) · Memorial Sloan Kettering Cancer Center (11) · M.D. Anderson Cancer Center (8) · Aura Biosciences (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · Vastra Gotaland Region (7) · Jonsson Comprehensive Cancer Center (6) · University of Southern California (6) · Delcath Systems Inc. (5) · IDEAYA Biosciences (5) · Thomas Jefferson University (5) · Case Comprehensive Cancer Center (4) · Emory University (4) · Immunocore Ltd (4)
United States (190) · France (33) · United Kingdom (25) · Germany (22) · Spain (22) · Australia (21) · Canada (20) · Netherlands (18) · Italy (13) · Belgium (9) · Sweden (8) · Switzerland (8) · Austria (7) · Poland (6) · Denmark (5)
Jeffrey S. Weber, MD, PhD (5) · Craig L. Slingluff, MD (3) · Jose Lutzky, MD (3) · Rino Seedor, MD (3) · Sapna Patel (3) · Wen-Jen Hwu, MD, PhD (3) · Alexander N Shoushtari (2) · Amy C. Schefler, MD (2) · Bradley R Straatsma, MD, JD (2) · Carin Gonsalves, MD (2) · F. Stephen Hodi, MD (2) · Francesco M. Marincola (2) · J. William Harbour, MD (2) · Jeffrey Weber (2)
PMID 25667295, PMID 29528792, PMID 12039921, PMID 12459649, PMID 12684398, PMID 12826605, PMID 12947072, PMID 15814645, PMID 16087944, PMID 16283570, PMID 16344433, PMID 17159027, PMID 17337065, PMID 17620582, PMID 18048828, PMID 18195220, PMID 18809608, PMID 19097774, PMID 19118701, PMID 20142553, PMID 20688739, PMID 20727190, PMID 21106722, PMID 22027909, PMID 22495394, PMID 23077008, PMID 23197414, PMID 23226204, PMID 23934701, PMID 24464266, PMID 24510314, PMID 24829756, PMID 24938562, PMID 25106493, PMID 25126421, PMID 25423330, PMID 25761109, PMID 26059332, PMID 26351350, PMID 26541511, PMID 27253171, PMID 27446211, PMID 27489285, PMID 27921276, PMID 28395880, PMID 28645940, PMID 28851380, PMID 30787124, PMID 30796035, PMID 31046743
P30CA008748 (4), 2019 (3), N01CM00039 (3), 2008 (2), 2023 (2), N01CM00100 (2), N01CM62203 (2), N01CM62206 (2), P30CA006973 (2), P30CA043703 (2), P30CA138292 (2), U01CA154967 (2), 2004 (1), 2014 (1), 2015 (1)